CYTOKINETICS INC

CEO Robert Blum’s discounted buy‑sell trades reveal Cytokinetics’ executive confidence amid market volatility—a balanced liquidity strategy that may signal long‑term growth prospects for muscle‑function therapeutics.

Insider buys Cytokinetics shares at $61.80, signaling confidence in its muscle‑modulating pipeline and long‑term upside potential.